Pharmaceutical sponsorship bias influences thrombolytic literature in acute ischemic stroke

about

Review article: Why is there still a debate regarding the safety and efficacy of intravenous thrombolysis in the management of presumed acute ischaemic stroke? A systematic review and meta-analysis.

P2860

Q30248290-8D886C0B-7B18-4AF6-B276-17CAE8908700

P2860

Pharmaceutical sponsorship bias influences thrombolytic literature in acute ischemic stroke

Item

http://www.wikidata.org/entity/Q35608208

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Pharmaceutical sponsorship bia ...... ature in acute ischemic stroke

@ast

Pharmaceutical sponsorship bia ...... ature in acute ischemic stroke

@en

type

Item

label

Pharmaceutical sponsorship bia ...... ature in acute ischemic stroke

@ast

Pharmaceutical sponsorship bia ...... ature in acute ischemic stroke

@en

prefLabel

Pharmaceutical sponsorship bia ...... ature in acute ischemic stroke

@ast

Pharmaceutical sponsorship bia ...... ature in acute ischemic stroke

@en

P1476

Pharmaceutical sponsorship bia ...... ature in acute ischemic stroke

@en

P2093

Ryan Patrick Radecki

http://www.w3.org/2001/XMLSchema#string

P2860

Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial--Italy (MAST-I) Group

Scope and impact of financial conflicts of interest in biomedical research: a systematic review

Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke

Tissue plasminogen activator for acute ischemic stroke

Is there evidence for biased reporting of published adverse effects data in pharmaceutical industry-funded studies?

Relationship between sponsorship and failure rate of dental implants: a systematic approach.

Alteplase for stroke: money and optimistic claims buttress the "brain attack" campaign.

Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism.

Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes.

Comparison of PubMed, Scopus, Web of Science, and Google Scholar: strengths and weaknesses.

P304

435-441

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5811/WESTJEM.2011.5.2166

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221728420

http://www.w3.org/2001/XMLSchema#string

P698

22224134

http://www.w3.org/2001/XMLSchema#string

P921

thrombolysis

bias

P932

3236136

http://www.w3.org/2001/XMLSchema#string

Pharmaceutical sponsorship bias influences thrombolytic literature in acute ischemic stroke

about

P2860

P2860

Pharmaceutical sponsorship bias influences thrombolytic literature in acute ischemic stroke

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P932